Today, 1:08 PM
- 7-Eleven and drone delivery service upstart Flirtey announce that they have completed the first fully autonomous drone delivery to a customer's residence. The pair says the development will help advance research toward integrating drones into the National Airspace System.
- The drone delivery in the Reno area, which marked the first time a U.S. customer has received a package to their home via drone, included Slurpee drinks, a chicken sandwich, donuts, hot coffee, and candy.
- Looking ahead, the two companies have plans to expand drone delivery tests and work closely together, according to a top 7-Eleven exec.
- Drone watch: While there's some speculation on the ways that companies such as Amazon (NASDAQ:AMZN), Wal-Mart (NYSE:WMT), Walgreens Boots Alliance (NASDAQ:WBA), and Domino's Pizza (NYSE:DPZ) could use drone delivery, many industry watchers think emergency conditions (flood/forest fire/earthquake/medical) or niche situations (oil rigs/barrier islands/inaccessible roads) are the most likely scenarios for widespread drone action. Earlier this year, an article in the MIT Technology Review speculated that an intermediary dropping off point out such as the local Starbucks (NASDAQ:SBUX) store could be utilized instead of working out all the problems of home delivery.
- Related (directly and tangentially) stocks: AMBA, AVAV, DJI, OTCQX:DRNE, HON, INVN, IXYS, GPRO, TRMB, FDX, UPS, TGT.
Wed, Jul. 20, 2:18 PM
- Rite Aid (RAD -1.9%) is lower after Bloomberg reports that a near-term resolution of the FTC's probe into the company's merger with Walgreens Boots Alliance (WBA +0.3%) is unlikely.
- Sources indicate the DOJ lawsuit blocking the Humana-Aetna merger could increase the pressure to reject a settlement on RAD/WBA.
Tue, Jul. 19, 11:26 AM
- Procter & Gamble (PG -0.3%) is testing an online subscription service for Tide Pods as it continues to slowly analyze the potential impact of a direct-to-consumer model.
- Last year, P&G introduced the Gillette Shave Club in an effort to match the upstart Dollar Shave Club. The late break by the company allowed the Dollar Shave Club to grow to 3.2M members.
- Though a significant shift could be years away, a push by Procter toward selling a higher mix of products through online subscription services could have an impact on retailers such as Target (TGT -0.2%), Wal-Mart (WMT), and Walgreen Boots Alliance (WBA -0.2%). It could also be a positive development for FedEx (FDX -0.5%) and UPS (UPS -0.4%).
Fri, Jul. 15, 9:19 AM
- There are some positive signs that the acquisition of Rite Aid (NYSE:RAD) by Walgreens Boots Alliance (NASDAQ:WBA) is on track, according to New York Post.
- Sources indicate that Walgreens is talking to the FTC about the extent of asset sales needed to gain approval and that some auctions are already taking place under the radar.
- Investors are biting on the news. Rite Aid is up 5.27% to $7.39 in premarket trading, although that's still far below the $9 per share deal price that was arranged last fall.
Wed, Jul. 13, 12:05 PM
Wed, Jul. 6, 12:31 PM
Wed, Jul. 6, 7:29 AM
- Walgreens Boots Alliance (NASDAQ:WBA) fiscal Q3 results ($M): Net Sales: 29,498 (+2.4%); Retail Pharmacy USA: 21,185 (+3.7%), Retail Pharmacy Intl: 3,194 (-2.3%), Pharmaceutical Wholesale: 5,748 (+0.7%).
- Operating Income: 1,533 (+9.4%); Non-GAAP Operating Income: 1,328 (+433.3); Net Income: 1,103 (-15.3%); EPS: 1.01 (-14.4%); Non-GAAP EPS: 1.18 (+15.7%); CF Ops (9 mo.): 5,189 (+24.8%).
- Fiscal 2016 Guidance: Non-GAAP EPS: $4.45 - 4.55 from $4.35 - 4.55.
- Shares are off a fraction premarket.
Wed, Jul. 6, 7:01 AM
Tue, Jul. 5, 5:30 PM
Tue, Jun. 14, 8:49 AM
- Retail sales topped expectations in May with some categories tipping off a healthy spending trend.
- Nonstore retailers once again led all categories with 12% Y/Y growth. Amazon (NASDAQ:AMZN) had a lot to say with that strong performance.
- Health and personal care stores were also solid with an 8% Y/Y rise in sales. Chains such as Walgreens (NASDAQ:WBA), Rite Aid (NYSE:RAD), Ulta Salon (NASDAQ:ULTA), and Sally Beauty Holdings (NYSE:SBH) continue to draw millennial interest.
- Department stores lagged once again with a 0.9% M/M drop and 6% Y/Y tail-off. A tough month of weather contributed to a 2% M/M drop in the building materials and garden equipment (HD, LOW) category.
- Restaurants performed ahead of expectations, sales were up 0.8% M/M and 6.5% Y/Y. That mark bodes well for McDonald's (NYSE:MCD) continuing its streak of staying in positive territory with comparable-store sales.
- Previously: Retail sales decelerate from April's pace (June 14)
- Retail ETFs: XLY, XRT, VCR, RTH, RETL, FXD, FDIS, RCD, PMR, JHMC, CNDF.
Sun, Jun. 12, 11:13 PM
- With regulators circling Theranos (Private:THER), Walgreens (NASDAQ:WBA) announces its intention to terminate its relationship with the blood-testing startup, and immediately close all 40 Theranos Wellness Centers at its stores.
- It's yet another blow to Theranos, as those centers are the company's primary source of revenue.
Fri, Jun. 10, 3:56 PM
- Shares of Walgreens Boots Alliance (WBA +4.4%) and Rite Aid <<RAD> > are both higher off of reports that the FTC is set to clear a path for the merger of the two drugstore chains.
- It's expected that the FTC will require some store closings and concessions with the pharmacy benefit manager business before granting a final approval.
Fri, Jun. 10, 7:19 AM
- Boston Scientific (NYSE:BSX) initiated with Buy rating and $26 (13% upside) price target by Guggenheim Securities.
- Zimmer Biomet Holdings (NYSE:ZBH) initiated with Neutral rating and $140 (18% upside) price target by Guggenheim Securities.
- Edwards Lifesciences (NYSE:EW) initiated with Neutral rating and $120 (18% upside) price target by Guggenheim Securities.
- Oncobiologics (Pending:ONS) initiated with Buy rating and $15 (218% upside) price target by Cantor Fitzgerald.
- Walgreens Boots Alliance (NASDAQ:WBA) reinstated with Buy rating and $95 (20% upside) price target by Bank of America.
- Goldman Sachs initiates coverage of specialty pharma with a Neutral rating: Buy: Jazz Pharma (NASDAQ:JAZZ) - $196 (26% upside) price target, Horizon Pharma (NASDAQ:HZNP) - $24 (30% upside) price target; Neutral: Endo International (NASDAQ:ENDP) - $20 (11% upside) price target, Mallinckrodt (NYSE:MNK) - $73 (17% upside) price target, Momenta Pharmaceuticals (NASDAQ:MNTA) - $14 (19% upside) price target; Concordia Healthcare (NASDAQ:CXRX) - $32 (31% upside) price target; Sell: Impax Laboratories (NASDAQ:IPXL) - $33 (2% downside risk) price target.
- Biocept (NASDAQ:BIOC) initiated with Buy rating and $1.20 (71% upside) price target by Roth Capital.
- Seres Therapeutics (NASDAQ:MCRB) initiated with Outperform rating and $40 (22% upside) price target by Cowen & Company.
- Omeros (NASDAQ:OMER) initiated with Buy rating and $21 (94% upside) price target by Cantor Fitzgerald.
- Glaukos (NYSE:GKOS) initiated with Buy rating and $35 (30% upside) price target by Cantor Fitzgerald.
- Shire plc (NASDAQ:SHPG) initiated with Overweight rating and GBX5,600 (34% upside) price target by Morgan Stanley.
Thu, May 26, 5:52 PM
- Walgreens Boots Alliance (NASDAQ:WBA) prices its $6B offering of unsecured unsubordinated notes. The tranches are:
- $1.25B 1.750% notes due 2018; $1.5B 2.600% notes due 2021; $750M 3.100% notes due 2023; $1.9B 3.450% notes due 2026 and $600M 4.650% notes due 2046.
- Net proceeds will fund a portion of the cash consideration in the Rite Aid deal, the retirement of a portion of Rite Aid's debt and related fees and expenses. Any remaining proceeds will be used for general corporate purposes. Closing date is June 1.
Thu, May 26, 5:23 AM
- Walgreens (NASDAQ:WBA) made a deal including plans to put Theranos (Private:THER) blood-testing centers in thousands of its stores despite never fully validating the startup's technology, according to a WSJ report.
- Before announcing the deal in 2013, some Walgreens executives and outside advisors had their doubts, but when pushed for answers, Theranos - in a way that went beyond Silicon Valley's endemic secrecy - provided few answers. Nevertheless, Walgreens moved forward anyway, in part because management felt Theranos might choose a different drugstore chain partner.
- Walgreens doesn't expect to recoup any of its at least $50M investment in Theranos.
Mon, May 16, 6:31 PM
- Jon Jacobson's Highfields Capital Management got out of Yahoo (YHOO +2.7%) and Microsoft (MSFT +1.5%) in Q1, and trimmed most of its stake in McDonald's (MCD +0.6%) while adding other consumer names, according to its 13F filing.
- The firm sold 12.79M shares of Microsoft (valued at $709.7M) and 7.14M shares of McDonald's ($808M), along with selling 7.2M shares of Yahoo (about $239.5M worth).
- It retains a stake of 4.76M shares of McDonald's. Meanwhile, it took a new position in Marriott (MAR +1.2%) -- 6.86M shares valued at $488.3M -- and bought 2.79M shares in Walgreens Boots Alliance (WBA +0.8%).
- Now read Microsoft - When Do Investors Get To See The Beef? »
Walgreens Boots Alliance, Inc. provides drug store services. It operates through the following segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Retail Pharmacy USA segment engages in pharmacy-led health and beauty retail businesses, which sells its... More
Industry: Drug Stores
Country: United States
Other News & PR